Wedbush Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $25

Moomoo NewsOct 1 08:34 ET · Ratings

LifeSci Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $24

Moomoo NewsOct 1 07:35 ET · Ratings

Buy Rating on Perspective Therapeutics Backed by Promising VMT-alpha-NET Clinical Results

TipRanksOct 1 07:16 ET · Ratings

Wedbush Initiates Perspective Therapeutics(CATX.US) With Buy Rating, Announces Target Price $25

Moomoo NewsSep 30 16:31 ET · Ratings

Perspective Therapeutics Initiated With an Outperform at Wedbush

TipRanksSep 30 16:05 ET · Ratings

Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine

GlobeNewswireSep 30 07:00 ET